Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Controlled, Open-label Extension (OLE) Study to Assess the Long-term Safety and Efficacy of AMG 145
Brief Summary: This study will contribute to the evaluation of long-term safety, tolerability and efficacy of evolocumab (AMG 145) in adults with hyperlipidemia and adults with mixed dyslipidemia.


Options:
A: Arm Label: Standard of Care; Type: ACTIVE_COMPARATOR; Interventions: Biological: Evolocumab, Drug: Standard of Care | Arm Label: Evolocumab + Standard of Care; Type: EXPERIMENTAL; Interventions: Biological: Evolocumab, Drug: Standard of Care | Intervention Type: BIOLOGICAL; Name: Evolocumab; Assigned to Arm(s): Evolocumab + Standard of Care, Standard of Care | Intervention Type: DRUG; Name: Standard of Care; Assigned to Arm(s): Evolocumab + Standard of Care, Standard of Care
B: Arm Label: Q28d Dosing Arm; Type: EXPERIMENTAL; Interventions: Drug: PBO, Drug: 200mg PF-04950615 (RN316), Drug: 300mg PF-04950615 (RN316) | Arm Label: Q14d Dosing Arm; Type: EXPERIMENTAL; Interventions: Drug: PBO, Drug: PF-04950615 | Intervention Type: DRUG; Name: PBO; Assigned to Arm(s): Q28d Dosing Arm | Intervention Type: DRUG; Name: 200mg PF-04950615 (RN316); Assigned to Arm(s): Q28d Dosing Arm | Intervention Type: DRUG; Name: 300mg PF-04950615 (RN316); Assigned to Arm(s): Q28d Dosing Arm | Intervention Type: DRUG; Name: PBO; Assigned to Arm(s): Q14d Dosing Arm | Intervention Type: DRUG; Name: PF-04950615; Assigned to Arm(s): Q14d Dosing Arm | Intervention Type: DRUG; Name: PF-04950615; Assigned to Arm(s): Q14d Dosing Arm | Intervention Type: DRUG; Name: PF-04950615; Assigned to Arm(s): Q14d Dosing Arm
C: Arm Label: Placebo Q2W; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (for alirocumab), Drug: Lipid-Modifying Therapy (LMT) | Arm Label: Alirocumab; Type: EXPERIMENTAL; Interventions: Drug: Alirocumab, Drug: Lipid-Modifying Therapy (LMT) | Intervention Type: DRUG; Name: Placebo (for alirocumab); Assigned to Arm(s): Placebo Q2W | Intervention Type: DRUG; Name: Alirocumab; Assigned to Arm(s): Alirocumab | Intervention Type: DRUG; Name: Lipid-Modifying Therapy (LMT); Assigned to Arm(s): Alirocumab, Placebo Q2W
D: Arm Label: Atorvastatin 40 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atorvastatin, Drug: Placebo | Arm Label: Ezetimibe 10 mg + Atorvastatin 20 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atorvastatin, Drug: Ezetimibe, Drug: Placebo | Arm Label: Alirocumab 75 mg/up to 150 mg + Atorvastatin 20 mg; Type: EXPERIMENTAL; Interventions: Drug: Alirocumab, Drug: Atorvastatin, Drug: Placebo | Arm Label: Atorvastatin 80 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atorvastatin, Drug: Placebo | Arm Label: Rosuvastatin 40 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Rosuvastatin, Drug: Placebo | Arm Label: Ezetimibe 10 mg + Atorvastatin 40 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atorvastatin, Drug: Ezetimibe, Drug: Placebo | Arm Label: Alirocumab 75 mg/ up to 150 mg + Atorvastatin 40 mg; Type: EXPERIMENTAL; Interventions: Drug: Alirocumab, Drug: Atorvastatin, Drug: Placebo | Intervention Type: DRUG; Name: Alirocumab; Assigned to Arm(s): Alirocumab 75 mg/ up to 150 mg + Atorvastatin 40 mg, Alirocumab 75 mg/up to 150 mg + Atorvastatin 20 mg | Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): Alirocumab 75 mg/ up to 150 mg + Atorvastatin 40 mg, Alirocumab 75 mg/up to 150 mg + Atorvastatin 20 mg, Atorvastatin 40 mg, Atorvastatin 80 mg, Ezetimibe 10 mg + Atorvastatin 20 mg, Ezetimibe 10 mg + Atorvastatin 40 mg | Intervention Type: DRUG; Name: Ezetimibe; Assigned to Arm(s): Ezetimibe 10 mg + Atorvastatin 20 mg, Ezetimibe 10 mg + Atorvastatin 40 mg | Intervention Type: DRUG; Name: Rosuvastatin; Assigned to Arm(s): Rosuvastatin 40 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Alirocumab 75 mg/ up to 150 mg + Atorvastatin 40 mg, Alirocumab 75 mg/up to 150 mg + Atorvastatin 20 mg, Atorvastatin 40 mg, Atorvastatin 80 mg, Ezetimibe 10 mg + Atorvastatin 20 mg, Ezetimibe 10 mg + Atorvastatin 40 mg, Rosuvastatin 40 mg

Answer: A